Melior Discovery Strengthens Scientific Leadership Team with Addition of Dr. Gregory Gatto and Biolucidation Assets

7/9/2013 6:25:19 AM

Melior Discovery, Inc. announced today that it has acquired all of the assets of Biolucidation, LLC and appointed its scientific founder, Dr. Gregory Gatto as Senior Director of Behavioral Pharmacology for Melior Discovery Inc. 

Dr. Gatto is a highly accomplished preclinical pharmacology expert with deep experience in the area of drug abuse liability. He has accumulated over 30 years of preclinical pharmacology research experience and over 15 years of pharmaceutical R&D experience in the area of psychiatric disease and cognition.

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.